20 July 2025 in Journal of Paediatrics and Child Health
Aim: To provide updated evidence‐based clinical guidance in the management of infants with bronchiolitis presenting to emergency departments (EDs), general paediatric, or intensive care units (ICUs) in Australia and Aotearoa New Zealand (AoNZ) following the first publication in 2016.Method: The Paediatric Research in Emergency Departments International Collaborative (PREDICT) network guideline working group appraised, summarised, and updated evidence from 1 January 2000 to 24 January 2024 addressing 41 questions (30 from the 2016 guideline and 11 new questions for 2025). Recommendations were developed using GRADE methodology and revised after a period of external consultation.Results: The literature search identified 26 467 citations with 431 included in 41 recommendations providing 11 new and 7 key updates. The key changes included: (i) refinement of the clinical features of bronchiolitis, (ii) addition of new risk factors for severity of illness, (iii) advice on the role of biomarkers for unexpected deterioration or admission to ICU, (iv) guidance on glucocorticoids in SARS‐CoV‐2 co‐infection, (v) guidance on combined glucocorticoids/inhaled epinephrine in severe bronchiolitis requiring ICU level care, (vi) refinement of oxygen saturation targets, (vii) guidance on humidified high flow therapy and continuous positive airway pressure, (viii) recommendation on use of RSV prevention therapies/immunisations for babies and mothers.Conclusion: The updated Australasian Bronchiolitis Guideline provides clinicians across Australasian settings with the latest evidence‐based guidance on the management of the commonest condition in infancy requiring hospital admission.
16 October 2020 in Archives of Disease in Childhood
Objective To determine if administration of oral prednisolone to preschool children with acute wheeze alters respiratory outcomes. Design Double-blind, randomised, placebo-controlled equivalence trial. Setting Three hospitals in New Zealand. Patients 477 children aged 24–59 months with acute wheeze associated with respiratory illness. Interventions 2 mg/kg (maximum 40 mg) oral prednisolone or similar placebo, once daily for 3 days. Main outcome measures Primary outcome was change in Preschool Respiratory Assessment Measure (PRAM) score 24 hours after intervention. Secondary outcomes included PRAM score at 4 hours, length of emergency department and inpatient stays, admission and representation rates, time to return to normal activities and use of additional oral prednisolone or intravenous medications. Analysis was by intention-to-treat. Results There was no difference between groups for change in PRAM score at 24 hours (difference between means −0.39, 95% CI −0.84 to 0.06, p=0.09). Absolute PRAM score was lower in the prednisolone group at 4 hours (median (IQR) 1 (0–2) vs 2 (0–3), p=0.01) and 24 hours (0 (0–1) vs 0 (0–1), p=0.01), when symptoms had resolved for most children regardless of initial treatment. Admission rate, requirement for additional oral prednisolone and use of intravenous medication were lower in the prednisolone group, although there were no differences between groups for time taken to return to normal activities or rates of representation within 7 days. Conclusion Oral prednisolone does not alter respiratory outcomes at 24 hours or beyond in preschool children presenting with acute wheeze.
23 April 2019 in Journal of Paediatrics and Child Health
Simulation has been increasingly used in the delivery of undergraduate paediatric medical education in recent years, particularly in the context of managing acutely unwell children. We describe our methodology in delivering a simulation workshop within a resource‐constrained setting, defined as a clinical environment limited by time, clinical duties and access to appropriate space and/or equipment. An outline for the workshop is provided, with examples of relevant resources, to facilitate the development of similar simulation teaching in other centres. Preliminary evaluation of student feedback is presented, exploring the learning points encountered and aspects of the workshop that students found useful.
27 July 2026 in Archives of Disease in Childhood
Objective: To compare the total direct healthcare costs of nasal high flow (NHF) therapy and standard oxygen therapy (SOT) as first-line treatments for paediatric acute hypoxaemic respiratory failure (AHRF) and to identify what factors explain variations in these costs. Design: Cost analysis following a randomised controlled trial. Setting: 14 hospitals across Australia and New Zealand. Patients: 1517 children aged 1–4 years admitted with AHRF between 18 December 2017 and 18 March 2020, enrolled in the Paediatric Acute Respiratory Intervention Study 2(PARIS-2) trial. Interventions: Patients were randomised to receive either NHF or SOT. Main outcome measures: Total and average cost per patient admission for the two first-line treatments of AHRF. Results: The total cost of treating the trial cohort was $A10 788 793 (US$7 660 143; €6 689 052; £6 041 724), corresponding to an average of $A7112 (US$5050; €4409; £3983) per patient. Average cost per patient admission was significantly higher in the NHF group at $A7815 (US$5549; €4845; £4376) compared with the SOT group at $A6419 (US$4557; €3980; £3595), with a mean difference of $A1396 (US$991; €866; £782, 95% CI $A419 to $A2372). Subgroup analyses showed that NHF non-responders, particularly those presenting with wheeze, incurred greater costs due to higher likelihood of intensive care admission and longer hospital stays. Conclusion: NHF costs more than SOT and does not lead to better clinical outcomes. Although NHF remains an important respiratory support modality for paediatric AHRF, its higher costs, particularly among those not responding to NHF, emphasise the need for more targeted use. Trial registration number: ACTRN12618000210279.